Recently, World Health Organization (WHO) published 12 lists of antibiotic-resistant, which represent the greatest threat to human health. The list was drawn up to be a guide and promote a research and development (R&D) of the new antibiotics, as part of the WHO's efforts to deliver the growing global resistance to antimicrobial pharmaceuticals.

According to The Guardian, the health experts have already warned that the resistance to the medicines that are used to fight infections could bring a bigger risk to humankind than cancer. These bacteria have built-in capacities to discover better approaches to resist the treatment and go along with the hereditary material that permits other bacteria to become a drug-resistant as well.

If the antibacterial medicines may lose its effectiveness, the key medical methods including organ transplantation, caesarean sections, joint replacement, and chemotherapy might turn out to be more dangerous to perform. It has 700,000 individuals around the globe die every year because of the drug-resistant infection, and it has been estimated that such infections will reach 10m of individuals will be dead by the year 2050.

The World Health Organization divided the list into three categories as indicated by the urgency of the requirement for the new antibiotics: critical, high, and medium priority. The most critical group of all includes multidrug resistant bacteria that represents a specific threat in hospitals, nursing homes, and among the patients whose care is needed a device such as ventilators and blood catheters.

The WHO hoped that this list would spur governments to set up an arrangement to boost the developments of the new medications. The list produced in a collaboration with the Division of Infectious Diseases at the University of Tübingen, Germany, by using a multi-care choice analysis method checked by a group of international specialists.

While R&D is vital, it is still cannot solve the problem alone. To address the resistance, there must be a better prevention of infections and suitable use of the existing antibiotic in humans and animals, and additionally a rational use of any new antibiotic agents that are produced in the future.

Related